Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
J Asthma
; 49(8): 839-42, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-22920591
ABSTRACT
BACKGROUND:
Omalizumab is a humanized monoclonal anti-IgE antibody that was recently approved for the treatment of severe allergic asthma. However, omalizumab is not licensed for allergic asthma in patients with a low serum IgE level (<30 IU/mL) or negative results for specific allergen tests. CASE HISTORY We present a patient with severe asthma and low serum IgE levels who had negative results for specific allergens induced by oral steroid therapy. Omalizumab administration improved asthma exacerbated forced expiratory volume in 1 s (FEV(1)) and respiratory resistance measurements based on the impulse oscillation technique (Mostgraph-01). The response to omalizumab therapy was evidenced by a decrease in airway resistance at 1 month.CONCLUSIONS:
The findings of this case report indicate that omalizumab treatment had beneficial effects in a patient with severe asthma and low total serum IgE levels with negative results for specific IgE, which may have been induced by long-term corticosteroid administration.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Asma
/
Inmunoglobulina E
/
Anticuerpos Antiidiotipos
/
Antiasmáticos
/
Anticuerpos Monoclonales Humanizados
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
J Asthma
Año:
2012
Tipo del documento:
Article
País de afiliación:
Japón